“Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York

Axel J. Adams, B.S., Samuel D. Banister, Ph.D., Lisandro Irizarry, M.D., Jordan Trecki, Ph.D., Michael Schwartz, M.D., M.P.H., and Roy Gerona, Ph.D.


BACKGROUND

New psychoactive substances constitute a growing and dynamic class of abused drugs in the United States. On July 12, 2016, a synthetic cannabinoid caused mass intoxication of 33 persons in one New York City neighborhood, in an event described in the popular press as a “zombie” outbreak because of the appearance of the intoxicated persons.

METHODS

We obtained and tested serum, whole blood, and urine samples from 8 patients among the 18 who were transported to local hospitals; we also tested a sample of the herbal “incense” product “AK-47 24 Karat Gold,” which was implicated in the outbreak. Samples were analyzed by means of liquid chromatography–quadrupole time-of-flight mass spectrometry.

RESULTS

The synthetic cannabinoid methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (AMB-FUBINACA, also known as MMB-FUBINACA or FUB-AMB) was identified in AK-47 24 Karat Gold at a mean (±SD) concentration of 16.0±3.9 mg per gram. The de-esterified acid metabolite was found in the serum or whole blood of all eight patients, with concentrations ranging from 77 to 636 ng per milliliter.

CONCLUSIONS

The potency of the synthetic cannabinoid identified in these analyses is consistent with strong depressant effects that account for the “zombielike” behavior reported in this mass intoxication. AMB-
FUBINACA is an example of the emerging class of “ultrapotent” synthetic cannabinoids and poses a public health concern. Collaboration among clinical laboratory staff, health professionals, and law enforcement agencies facilitated the timely identification of the compound and allowed health authorities to take appropriate action.

“Zombie” Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York

Axel J. Adams, B.S., Samuel D. Banister, Ph.D., Lisandro Irizarry, M.D., Jordan Trecki, Ph.D., Michael Schwartz, M.D., M.P.H., and Roy Gerona, Ph.D.


Commonly abused drugs are undergoing a period of proliferation and diversification, with a corresponding increase in the challenges faced by emergency and critical care physicians, substance abuse professionals, psychiatrists, and toxicologists. New psychoactive substances provide users with alternatives to older and better-characterized drugs of abuse, such as amphetamines, heroin, cocaine, and cannabis. Of the more than 540 new psychoactive substances that have been reported to the United Nations Office on Drugs and Crime, synthetic cannabinoids are the fastest growing class, with more than 177 identified by the agency in 2014 and 24 new synthetic cannabinoids reported by Europol in 2015.1-3 Initially developed by academic chemists and pharmaceutical scientists in the United States and Europe as ligands for studying the endocannabinoid system, synthetic cannabinoids share no structural commonality with the plant cannabinoid Δ⁹-tetrahydrocannabinol (Δ⁹-THC) found in cannabis4 (Figure 1).
Synthetic cannabinoids shifted from research tools to drugs of abuse in 2008, when herbal mixtures known as the brands “Spice” (in Europe) and “K2” (in North America) were found to contain JWH-018 and CP 47,497-C8. Since then, new synthetic cannabinoids have been developed in clandestine laboratories in China and South Asia and distributed by “darknet” retailers (e.g., Silk Road, Silk Road 2.0, and Pandora), street drug dealers, and organized-crime groups as inexpensive alternatives to traditional drugs of abuse. Figure 1 provides a summary of the structural changes that have been found in these drugs since surveillance started in 2009.

Typically, synthetic cannabinoids are dissolved in solvent, applied to an inert herbal substrate, and smoked in a fashion similar to cannabis. In the past 8 years, synthetic cannabinoids have been associated with serious adverse effects. The undesirable effects most commonly reported by users include drowsiness, lightheadedness, and fast or irregular heartbeat. More severe clinical features, including psychosis, delirium, cardiotoxicity, seizures, acute kidney injury, hyperthermia, and death, have also been noted. Depression of the central nervous system (CNS) is consistent with the potent cannabinoid receptor 1 agonist activity that has been reported for many synthetic cannabinoids, cardiotoxicity may be due to inhibition of the alpha subunit of potassium channels in cardiomyocytes, and autonomic symptoms may be due to the affinity of some cannabinoids for serotonin 2B receptors. Some synthetic cannabinoids also possess agonist activity at dopamine receptors in vitro and substantial changes in dopamine signaling have been observed in a cannabinoid user in the midst of a severe withdrawal syndrome. The synthetic cannabinoid AB-FUBINACA (Figure 1) was developed by Pfizer and described in a patent in 2009. AB-FUBINACA was first identified in synthetic cannabinoid products in Japan in 2012 and was designated as a Schedule I controlled substance in the United States in January 2014. On July 3, 2014, an ester analogue of AB-FUBINACA, methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (AMB-FUBINACA), was discovered in a product called “Train Wreck 2” in Louisiana and was immediately prohibited through emergency rule by the State of Louisiana. More recently, AMB-FUBINACA appeared in a product found in New York City that resulted in the hospitalization of multiple persons on the morning of July 12, 2016, and turned a block in the Bedford–Stuyvesant area of Brooklyn into what was described by the lay press as a “zombieland.”

DESCRIPTION OF INDEX PATIENT

On July 12, 2016, the New York City Emergency Medical Services (EMS) was dispatched to the scene of a multiple-casualty incident in the borough of Brooklyn in New York City. First responders reported that there were multiple persons at the scene, all of whom had a degree of altered mental status that was described by bystanders as “zombielike.” Subsequent media reports of the outbreak on July 12, 2016, identified 33 persons exposed to an unknown drug, of whom 18 (number confirmed by law enforcement) were transported to two local medical centers. The ages of the persons requiring transport were 25 to 59 years (mean, 36.8 years), and all the persons were male. Eight of the persons identified themselves to emergency medical staff as homeless.
The clinical features in this outbreak were typified by the index patient, a man who was 28 years of age
and who was described by EMS providers at the scene as being slow to respond to questioning and as
having a “blank stare.” Prehospitalization interventions included the administration of supplemental
oxygen and cardiac monitoring. In the emergency department, the patient was lethargic but arousable
to tactile stimuli. His heart rate was 88 beats per minute, blood pressure 101/61 mm Hg, respiratory
rate 21 breaths per minute, body temperature 36.7°C (98°F) orally, and oxygen saturation 95% while
he was breathing ambient air. Physical examination revealed no evidence of trauma. The pupils in
both eyes were 4 mm and reactive; there was no facial asymmetry or excessive salivation noted. The
patient was sweating. His lungs were clear to auscultation, and his heart sounds were normal. His
bowel sounds were normoactive, and a skin examination revealed no evidence of excessive sweating,
flushing, or lesions. The patient had no focal neurologic findings and no hyperreflexia or increased
muscle tone. His overall score on the Glasgow Coma Scale was 13 (scores range from 3 to 15, with 15
being normal); his scores for eye response and for verbal response were 4, and his score for motor
response was 5. He had intermittent periods of “zombielike” groaning and slow mechanical
movements of the arms and legs.
Laboratory analysis, including a complete blood count, a comprehensive metabolic panel, urinalysis,
and a urine immunoassay screening test for amphetamines, cocaine, phencyclidine, opiates,
methadone, THC, barbiturates, benzodiazepines, tricyclic antidepressants, and serum ethanol level
revealed no abnormalities. An electrocardiogram showed a normal sinus rhythm without evidence of
acute myocardial injury or conduction abnormalities. Normal results of routine laboratory testing were
found in the other seven patients who were treated at the same hospital.
The patient was placed in the observation unit; his lethargy resolved and his behavior normalized
approximately 9 hours after his arrival. He offered no further clarifying history other than to confirm a
first-time inhalational exposure to the substance contained in a packet, and he was discharged.
A description of the collaborative work among clinicians and various agencies that was undertaken
from the time of the outbreak until the causative agent was identified is summarized in Figure
2FIGURE 2.Timeline and Workflow of Collaboration Leading to the Resolution of the
Outbreak. The Drug Enforcement Administration (DEA) and the Office of Health Affairs of the
Department of Homeland Security became aware of this outbreak because of its scale and rapid
evolution and because of the media coverage. On the basis of the fact that this was a large local
outbreak and that the mode of drug exposure was smoking, it seemed possible that a potent synthetic
cannabinoid agonist was involved, but patient interviews provided no indication of the identity of the
compound. The DEA subsequently obtained biologic samples from 8 of the 18 patients in the outbreak
who were transported for medical care, including the patient described above, and sent the samples to
their collaborators for comprehensive drug analysis with the use of high-resolution mass spectrometry. In addition, a sample of the product that had been smoked by another patient who was brought to the emergency department and that had been turned over to the New York City Department of Health and Mental Hygiene and given to the New York Police Department Crime Laboratory was also analyzed.

The implicated product — “AK-47 24 Karat Gold,” shown in Figure 3 — consisted of agglutinated herbal material that had been divided into aliquots in eight small blue bags.

METHODS

Several aliquots of the product (AK-47 24 Karat Gold) and blood and urine samples from eight patients were sent to the Clinical Toxicology and Environmental Biomonitoring Laboratory at the University of California, San Francisco. Samples were analyzed by means of liquid chromatography–quadrupole time-of-flight mass spectrometry (LC–QTOF/MS) (Agilent LC 1260-QTOF/MS 6550). Quantitative analysis of each confirmed drug or metabolite was performed with the use of the isotope dilution method with a 10-point calibration curve. Further details of the toxicologic analyses are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.

RESULTS

Analysis of the Material Recovered by the Police

LC–QTOF/MS analysis of the herbal product revealed a unique signal at a concentration of 1 mg per milliliter, which corresponded to AMB-FUBINACA. The signal was cross-referenced and confirmed by comparison with an analytic standard and the published literature.27 The concentration of AMB-FUBINACA in several samples from the product ranged from 14.2 to 25.2 mg per gram, with a mean (±SD) concentration of 16.0±3.9 mg per gram (Table 1). AMB-FUBINACA was confirmed in a swab taken from the interior of the foil wrapper.

Analysis of Blood and Urine from the Patients

No AMB-FUBINACA parent compound was detected in the blood or urine of the patients, but its de-esterified acid metabolite, 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoic acid, was detected in every patient, with serum concentrations ranging from 77 to 636 ng per milliliter (or
Concentrations of the AMB-FUBINACA Acid Metabolite and Other Drugs Found in Samples from the Patients. The urine concentration of the acid metabolite of AMB-FUBINACA was 165 ng per milliliter in the sample from Patient C and was below the limit of detection in the sample from Patient E. No other illicit drugs were observed in samples obtained from the patients. In one set of serial serum samples (from Patient C), clearance of the drug was observed as the serum concentration decreased from 245 to 155 ng per milliliter over a period of 14 hours.

DISCUSSION

AMB-FUBINACA is a potent indazole synthetic cannabinoid that reflects the continued evolution of chemical structures of cannabinoid receptor agonists (Figure 1). Recent in vitro pharmacologic studies of the actions of AMB-FUBINACA at the cannabinoid receptor 1 indicate that it is 85 times as potent as Δ⁹-THC and 50 times as potent as JWH-018, which was found in the early outbreaks of “K2” synthetic cannabinoid products. The potency of AMB-FUBINACA is consistent with strong CNS depressant effects that would account for the “zombielike” behavior of the users that was reported in this mass intoxication. Descriptions found on online drug forums (e.g., Reddit) regarding AMB-FUBINACA use terms such as “out of this world potent” with regard to its effects, which are described as being subjectively similar to those of Δ⁹-THC.

Despite the potential for overdose, increasingly potent synthetic cannabinoids may have become popular with drug dealers and users because of their low cost and potential for dilution into large volumes of product. A recent Internet query for purchase of AMB-FUBINACA powder showed prices of $1.95 to $3.80 per gram ($1,950 to $3,800 per kilogram). As shown in Table 1, the mean concentration of AMB-FUBINACA found in the packet recovered from the scene described in this report was 16.0 mg per gram. To obtain a 16-mg-per-gram product, a manufacturer could mix 1 kg of AMB-FUBINACA with 66.7 kg of plant material and produce approximately 15,625 packets, each containing 4 g of the product, with an online price averaging $35 per packet.

The absence of the parent compound, AMB-FUBINACA, in the biologic samples that were analyzed is typical for short-acting, potent psychoactive substances. For most esterified drugs, such as AMB-FUBINACA, hydrolysis occurs rapidly after intake, and the corresponding acid metabolites are detectable in biologic samples; the parent compound, however, may be detectable only at low levels. For example, the only other serum value reported in the literature for any esterified indazole synthetic cannabinoid parent compound (5F-AMB, 0.19 ng per milliliter) is far below the range we observed for metabolites in biologic samples obtained in this outbreak. The concentration of AMB-FUBINACA metabolite observed in serum samples in this case series is similar to the range observed in samples from patients with intoxication caused by a different indazole synthetic cannabinoid (ADB-PINACA) that caused severe delirium in an outbreak in Georgia in
The severe behavioral alteration observed in the patients in New York City and reported by
the press is consistent with the potent cannabinoid activity of AMB-FUBINACA; intoxication with this
agent is unusual in that extreme CNS depression is not accompanied by the tachycardia, arrhythmia,
seizures, hyperthermia, cardiotoxicity, and acute kidney injury that are usually found in association with
potent or high doses of synthetic cannabinoid. In both the New York and the Georgia outbreaks, there
may have been selection bias toward more severe cases because most of the samples analyzed were
obtained from hospitals that received the most heavily intoxicated patients.

The cause of a cluster of serious intoxications by a new drug is usually not familiar to the medical
community until it is first described in a case series. Identification of the responsible agent requires
collaboration among clinical laboratories, health professionals, law enforcement agencies, and
synthetic organic chemists so that timely information about the causative agent can be disseminated.

The analysis of new psychoactive substances requires more than the typical targeted drug panels
used in emergency departments and relies on more sophisticated analytic platforms that have the
ability to rapidly identify previously unreported compounds. The clinical history provided by medical
professionals aids in toxicologic analysis by eliminating well-characterized agents such as cocaine,
heroin, and methamphetamine. The law enforcement agencies involved during an outbreak may be
able to provide products and paraphernalia collected during mass intoxications for analysis. This may
be especially important when very low concentrations of the drug or its metabolites are present in
biologic samples. Finally, the ability to predict and rapidly generate reference standards for new drugs
and their metabolites allows for the identification of previously unknown new psychoactive substances
for which commercial reference standards are not available for many months after identification of the
compound.31 The collaborations in the current AMB-FUBINACA outbreak allowed for characterization
of the responsible synthetic cannabinoid in only 17 days. As the number and complexity of new
psychoactive substances increases, this type of coordination among multiple agencies is important for
the timely resolution of future outbreaks.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of
the Department of Homeland Security or its components or of the Drug Enforcement Administration.
This article was published on December 14, 2016, at NEJM.org.

We thank Thomas Hickey and Donald Brown from the New York Police Department, Dr. W. Thelmo, Deborah
Sirica, and Jazzette Rivera from the Wyckoff Heights Medical Center, and Lynnette Holder from the Woodhull
Medical Center for their assistance throughout this outbreak; and Justine Menager, Camille Jaligot, and Assan
Sanogo of the Faculté de Pharmacie, Université d’Auvergne, for assistance in the analysis of samples submitted
from the outbreak.

SOURCE INFORMATION

From the Clinical Toxicology and Environmental Biomonitoring Laboratory (A.J.A., R.G.) and School of Medicine
(A.J.A.), University of California, San Francisco, San Francisco, and the Department of Radiation Oncology,
Stanford University School of Medicine, Palo Alto (S.D.B.) — both in California; the Department of Emergency
Medicine, Wyckoff Heights Medical Center, New York (L.I.); the Office of Diversion Control, Drug and Chemical
Evaluation Section, Drug Enforcement Administration, Springfield, VA (J.T.); and the Chemical Defense Program,
Address reprint requests to Dr. Gerona at roy.gerona@ucsf.edu.